|
Play Video: The Importance of Insider Buying
|
|
|
The table below summarizes the most recent Taysha Gene Therapies insider buying information, with links below the price to see the
CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many
possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more
information about why Taysha Gene Therapies insider buys are important for investors to follow.
Date | Insider | Price | Amount |
11-17-2023 Insider Buy |
Paul B. Manning >10% Owner |
$1.63
CAGR »
|
$163,000.00 100,000 shares |
8-16-2023 Insider Buy |
Paul B. Manning >10% Owner |
$0.90
CAGR »
|
$14,820,000.30 16,466,667 shares |
8-16-2023 Insider Buy |
Phillip B. Donenberg Director |
$0.90
CAGR »
|
$99,999.90 111,111 shares |
8-16-2023 Insider Buy |
Sean P. Nolan Chief Executive Officer |
$0.90
CAGR »
|
$399,999.60 444,444 shares |
8-16-2023 Insider Buy |
John A. Stalfort III Director |
$0.90
CAGR »
|
$700,000.20 777,778 shares |
10-31-2022 Insider Buy |
Paul B. Manning Director and >10% Owner |
$2.00
CAGR »
|
$3,000,000.00 1,500,000 shares |
2-3-2022 Insider Buy |
Paul B. Manning Director and >10% Owner |
$7.80
CAGR »
|
$1,571,809.68 201,602 shares |
2-2-2022 Insider Buy |
Sukumar Nagendran Director |
$8.01
CAGR »
|
$80,100.00 10,000 shares |
2-2-2022 Insider Buy |
Phillip B. Donenberg Director |
$7.78
CAGR »
|
$23,340.00 3,000 shares |
11-23-2021 Insider Buy |
R.A. Session II President and CEO |
$12.44
CAGR »
|
$529,102.40 42,518 shares |
11-24-2021 Insider Buy |
Paul B. Manning Director and >10% Owner |
$13.19
CAGR »
|
$29,044.38 2,202 shares |
11-23-2021 Insider Buy |
Paul B. Manning Director and >10% Owner |
$12.54
CAGR »
|
$250,800.00 20,000 shares |
5-20-2021 Insider Buy |
Sean P. Nolan Director |
$22.35
CAGR »
|
$26,149.50 1,170 shares |
5-14-2021 Insider Buy |
Paul B. Manning Director and >10% Owner |
$20.98
CAGR »
|
$251,760.00 12,000 shares |
Also See: Institutional Holders of TSHA
Also See: SEC filings
Below we present the annualized performance delivered by Taysha Gene Therapies stock since 11-17-2023 (the date of the most recent
insider purchase). The performance of the investment from the time Taysha Gene Therapies insider buying occurred is the ultimate
test of whether insiders were right about TSHA being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
11/20/2023 |
|
End date: |
05/08/2024 |
|
Start price/share: |
$1.80 |
|
End price/share: |
$2.38 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
32.22% |
|
Annualized Gain: |
69.59% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$13,222.00 |
|
Years: |
0.46 |
|
Taysha Gene Therapies Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent Taysha Gene Therapies insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding TSHA
|
|